Efficacy and safety of sucroferric oxyhydroxide in the treatment of hyperphosphataemia in chronic kidney disease in Asturias. FOSFASTUR study.

Autor:	Sanchez-Alvarez JE; Servicio de Nefrología, Hospital Universitario de Cabueñes, Gijón, Asturias, Spain. Electronic address: jesastur@hotmail.com., Astudillo Cortés E; Servicio de Otorrinolaringologia, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain., Seras Mozas M; Servicio de Nefrología, Hospital Universitario San Agustin, Avilés, Asturias, Spain., García Castro R; Servicio de Nefrología, Fundación Hospital de Jove, Gijón, Asturias Spain., Hidalgo Ordoñez CM; Servicio de Nefrología, Hospital Vital Álvarez Buylla, Mieres, Asturias, Spain., Andrade López AC; Servicio de Nefrología, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain., Ulloa Clavijo C; Servicio de Nefrología, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain., Gallardo Pérez A; Servicio de Nefrología, Hospital Universitario San Agustin, Avilés, Asturias, Spain., Rodríguez Suarez C; Servicio de Nefrología, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.
Jazyk:	angličtina
Zdroj:	Nefrologia [Nefrologia (Engl Ed)] 2021 Jan-Feb; Vol. 41 (1), pp. 45-52. Date of Electronic Publication: 2021 Mar 01.
DOI:	10.1016/j.nefroe.2021.02.005
Abstrakt:	Alterations in bone and mineral metabolism are very common in chronic kidney disease (CKD). The increase in phosphate levels leads to bone disease, risk of calcification and greater mortality, so any strategy aimed at reducing them should be welcomed. The latest drug incorporated into the therapeutic arsenal to treat hyperphosphataemia in CKD is Sucroferric Oxyhydroxide (SFO). Objective: To analyse the efficacy and safety of OSF in three cohorts of patients, one with advanced chronic kidney disease not on dialysis (CKD-NoD), another on peritoneal dialysis (PD) and the last on haemodialysis (HD), followed for six months. Methods: A prospective, observational, multicentre study in clinical practice. Clinical and epidemiological variables were analysed. The evolution of parameters relating to alterations in bone and mineral metabolism and anaemia was analysed. Results: Eighty-five patients were included in the study (62 ± 12 years, 64% male, 34% diabetic), 25 with CKD-NoD, 25 on PD and lastly, 35 on HD. In 66 patients (78%), SFO was the first phosphate binder; in the other 19, SFO replaced a previous phosphate binder due to poor tolerance or efficacy. The initial dose of SFO was 964 ± 323 mg/day. Overall, serum phosphate levels saw a significant reduction at three months of treatment (19.6%, P < 0.001). There were no differences in the efficacy of the drug when the different populations analysed were compared. Over the course of the study, there were no changes to levels of calcium, PTHi, ferritin, or the transferrin and haemoglobin saturation indices, although there was a tendency for the last two to increase. Twelve patients (14%) withdrew from follow-up, ten due to gastrointestinal adverse effects (primarily diarrhoea) and two were lost to follow-up (kidney transplant). The mean dose of the drug that the patients received increased over time, up to 1147 ± 371 mg/day. Conclusions: SFO is an effective option for the treatment of hyperphosphataemia in patients with CKD both in the advanced phases of the disease and on dialysis. We found similar efficacy across the three groups analysed. The higher their baseline phosphate level, the greater the reduction in the serum levels. A notable reduction in phosphate levels can be achieved with doses of around 1000 mg/day. Diarrhoea was the most common side effect, although it generally was not significant. (Copyright © 2020 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu